Prescription psychostimulants for the treatment of amphetamine‐type stimulant use disorder: A systematic review and meta‐analysis of randomized placebo‐controlled trials
Addiction · 2024-02 · 119 (2) · 211-224
DOI: 10.1111/add.16347 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Addiction, online erschienen am 25.10.2023. Verfasst von Heidar Sharafi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada. Hauptthemen laut MEDLINE: Central Nervous System Stimulants, Methylphenidate, Substance-Related Disorders. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Institutes of Health Research (CIHR), Université de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM).
Abstract (Originalsprache)
Background and Aims There is currently no standard of care for pharmacological treatment of amphetamine‐type stimulant (ATS) use disorder (ATSUD). This systematic review with meta‐analysis (PROSPERO CRD42022354492) aimed to pool results from randomized placebo‐controlled trials (RCTs) to evaluate efficacy and safety of prescription psychostimulants (PPs) for ATSUD.
Methods
Major indexing sources and trial registries were searched to include records published before 29 August 2022. Eligible studies were RCTs evaluating efficacy and safety of PPs for ATSUD. Risk of bias (RoB) was assessed using the Cochrane RoB 2 tool. Risk ratio (RR) and risk difference were calculated for random‐effect meta‐analysis of dichotomous variables. Mean difference and standardized mean difference (SMD) were calculated for random‐effect meta‐analysis of continuous variables.
Results
Ten RCTs ( n = 561 participants) were included in the meta‐analysis. Trials studied methylphenidate ( n = 7), with daily doses of 54–180 mg, and dextroamphetamine ( n = 3), with daily doses of 60–110 mg, for 2–24 weeks. PPs significantly decreased end‐point craving [SMD −0.29; 95% confidence interval (CI) = −0.55, −0.03], while such a decrease did not reach statistical significance for ATS use, as evaluated by urine analysis (UA) (RR = 0.93; 95% CI = 0.85–1.01). No effect was observed for self‐reported ATS use, retention in treatment, dropout following adverse events, early‐stage craving, withdrawal and depressive symptoms. In a sensitivity analysis, treatment was associated with a significant reduction in UA positive for ATS (RR = 0.89; 95% CI = 0.79–0.99) after removing studies with a high risk of bias. In subgroup analyses, methylphenidate and high doses of PPs were negatively associated with ATS use by UA, while higher doses of PPs and treatment duration (≥ 20 weeks) were positively associated with longer retention.
Conclusions
Among individuals with amphetamine‐type stimulant use disorder, treatment with prescription psychostimulants may decrease ATS use and craving. While effect size is limited, it may increase with a higher dosage of medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada.
- Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal, Canada.
- Department of Medicine, University of British Columbia, Vancouver, Canada.
- British Columbia Centre on Substance Use, St Paul's Hospital, Vancouver, Canada.
- National Centre for Clinical Research on Emerging Drugs (NCCRED), University of New South Wales, Sydney, Australia.
- St Vincent's Hospital Sydney Alcohol and Drug Service, Darlinghurst, Australia.
ORCID-Profile: Paxton Bach, Vitor S Tardelli, Didier Jutras-Aswad
Förderung
- Canadian Institutes of Health Research (CIHR)
- Université de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM)
Zitieren
APA
Sharafi, H., Bakouni, H., McAnulty, C., Drouin, S., Coronado-Montoya, S., Bahremand, A., Bach, P., Ezard, N., Le Foll, B., Schütz, C. G., Siefried, K. J., Tardelli, V. S., Ziegler, D., & Jutras-Aswad, D. (2024). Prescription psychostimulants for the treatment of amphetamine‐type stimulant use disorder: A systematic review and meta‐analysis of randomized placebo‐controlled trials. Addiction, 119(2), 211-224. https://doi.org/10.1111/add.16347
Vancouver
Sharafi H, Bakouni H, McAnulty C, Drouin S, Coronado-Montoya S, Bahremand A, et al. Prescription psychostimulants for the treatment of amphetamine‐type stimulant use disorder: A systematic review and meta‐analysis of randomized placebo‐controlled trials. Addiction. 2024;119(2):211-224. doi:10.1111/add.16347
BibTeX
@article{Sharafi2024,
author = {Sharafi, Heidar and Bakouni, Hamzah and McAnulty, Christina and Drouin, Sarah and Coronado-Montoya, Stephanie and Bahremand, Arash and Bach, Paxton and Ezard, Nadine and Le Foll, Bernard and Schütz, Christian G and Siefried, Krista J and Tardelli, Vitor S and Ziegler, Daniela and Jutras-Aswad, Didier},
title = {Prescription psychostimulants for the treatment of amphetamine‐type stimulant use disorder: A systematic review and meta‐analysis of randomized placebo‐controlled trials},
journal = {Addiction},
year = {2024},
volume = {119},
number = {2},
pages = {211--224},
doi = {10.1111/add.16347}
}
EUVIMED